Anti-inflammatory Effects of Hinokitiol on Human Corneal Epithelial Cells: an in Vitro Study

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2015 May 9

PMID 25952949

Citations 9

Authors

J Ye

Y-F Xu

L-X Lou

K Jin

Q Miao

X Ye

Y Xi

Affiliations

Soon will be listed here.

Abstract

Purpose: This study assessed the anti-inflammatory effect and mechanism of action of hinokitiol in human corneal epithelial (HCE) cells.

Methods: HCE cells were incubated with different concentrations of hinokitiol or dimethylsulfoxide (DMSO), which served as a vehicle control. Cell viability was evaluated using Cell Counting Kit-8 (CCK-8) assay. After polyriboinosinic:polyribocytidylic acid (poly(I:C)) stimulus, cells with or without hinokitiol were evaluated for the mRNA and protein levels of interleukin-8 (IL-8), interleukin-6 (IL-6), and interleukin-1β (IL-1β) using real-time PCR analysis and an enzyme-linked immunosorbent assay (ELISA), respectively. Nuclear and cytoplasmic levels of nuclear factor kappa B (NF-κB) p65 protein and an inhibitor of NF-κB α (IκBα) were evaluated using western blotting.

Results: There were no significant differences among the treatment concentrations of hinokitiol compared with cells incubated in medium only. Incubating with 100 μM hinokitiol significantly decreased the mRNA levels of IL-8 to 58.77±10.41% (P<0.01), IL-6 to 64.64±12.71% (P<0.01), and IL-1β to 54.19±8.10% (P<0.01) compared with cells stimulated with poly(I:C) alone. The protein levels of IL-8, IL-6, and IL-1β had similar trend. Further analysis revealed that hinokitiol maintained the levels of IκBα and significantly reduced NF-κB p65 subunit translocation to the nucleus which significantly inhibiting the activation of the NF-κB signal pathway.

Conclusion: Hinokitiol showed a significant protective effect against ocular surface inflammation through inhibiting the NF-κB pathway, which may indicate the possibility to relieve the ocular surface inflammation of dry eye syndrome (DES).

Citing Articles

Studies on the antifungal effects of Hinokitiol on Candida albicans: inhibition of germ tube formation and synergistic pharmacological effects of miconazole.

Takeuchi N, Fukui K, Nakamura K, Tanaka A Odontology. 2024; .

PMID: 39292415 DOI: 10.1007/s10266-024-00992-4.

Therapeutic Effects of Hinokitiol through Regulating the SIRT1/NOX4 against Ligature-Induced Experimental Periodontitis.

Kim T, Kim E, Jeong G Antioxidants (Basel). 2024; 13(5).

PMID: 38790655 PMC: 11118509. DOI: 10.3390/antiox13050550.

Hinokitiol-iron complex is a ferroptosis inducer to inhibit triple-negative breast tumor growth.

Zhao H, Zhang M, Zhang J, Sun Z, Zhang W, Dong W Cell Biosci. 2023; 13(1):87.

PMID: 37179385 PMC: 10182687. DOI: 10.1186/s13578-023-01044-0.

Different Cell Responses to Hinokitiol Treatment Result in Senescence or Apoptosis in Human Osteosarcoma Cell Lines.

Yang S, Chen H, Chuang W, Wang H, Hsieh C, Huang Y Int J Mol Sci. 2022; 23(3).

PMID: 35163553 PMC: 8835861. DOI: 10.3390/ijms23031632.

Effects of Hinokitiol and Dicalcium Phosphate on the Osteoconduction and Antibacterial Activity of Gelatin-Hyaluronic Acid Crosslinked Hydrogel Membrane In Vitro.

Chang K, Chen W, Haung S, Liu S, Lin C Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451899 PMC: 8401089. DOI: 10.3390/ph14080802.

References

Morita Y, Matsumura E, Okabe T, Fukui T, Shibata M, Sugiura M . Biological activity of alpha-thujaplicin, the isomer of hinokitiol. Biol Pharm Bull. 2004; 27(6):899-902. DOI: 10.1248/bpb.27.899. View

Lee A, Lee J, Saw S, Gazzard G, Koh D, Widjaja D . Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002; 86(12):1347-51. PMC: 1771386. DOI: 10.1136/bjo.86.12.1347. View

Barber L, Pflugfelder S, Tauber J, Foulks G . Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005; 112(10):1790-4. DOI: 10.1016/j.ophtha.2005.05.013. View

Dana M, Hamrah P . Role of immunity and inflammation in corneal and ocular surface disease associated with dry eye. Adv Exp Med Biol. 2003; 506(Pt B):729-38. DOI: 10.1007/978-1-4615-0717-8_103. View

Yoshida I, Azuma M . An alternative receptor to poly I:C on cell surfaces for interferon induction. Microbiol Immunol. 2013; 57(5):329-33. DOI: 10.1111/1348-0421.12050. View

Niederkorn J, Stern M, Pflugfelder S, de Paiva C, Corrales R, Gao J . Desiccating stress induces T cell-mediated Sjögren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006; 176(7):3950-7. DOI: 10.4049/jimmunol.176.7.3950. View

de Paiva C, Pflugfelder S . Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol. 2009; 71(6 Suppl):89-95. DOI: 10.1590/s0004-27492008000700017. View

Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J . Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. Am J Physiol Cell Physiol. 2001; 281(2):C595-602. DOI: 10.1152/ajpcell.2001.281.2.C595. View

Ueta M, Hamuro J, Kiyono H, Kinoshita S . Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res Commun. 2005; 331(1):285-94. DOI: 10.1016/j.bbrc.2005.02.196. View

10.

Fabre E, Bureau J, Pouliquen Y, LORANS G . Binding sites for human interleukin 1 alpha, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal cornea and keratoconus. Curr Eye Res. 1991; 10(7):585-92. DOI: 10.3109/02713689109013850. View

11.

Nichols K, Foulks G, Bron A, Glasgow B, Dogru M, Tsubota K . The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011; 52(4):1922-9. PMC: 3072157. DOI: 10.1167/iovs.10-6997a. View

12.

Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K . Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013; 32(9):1219-23. DOI: 10.1097/ICO.0b013e318294f97e. View

13.

Vallabhapurapu S, Karin M . Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009; 27:693-733. DOI: 10.1146/annurev.immunol.021908.132641. View

14.

Jayakumar T, Hsu W, Yen T, Luo J, Kuo Y, Fong T . Hinokitiol, a natural tropolone derivative, offers neuroprotection from thromboembolic stroke in vivo. Evid Based Complement Alternat Med. 2013; 2013:840487. PMC: 3826376. DOI: 10.1155/2013/840487. View

15.

Javadi M, Feizi S . Dry eye syndrome. J Ophthalmic Vis Res. 2012; 6(3):192-8. PMC: 3306104. View

16.

Takamura E, Tsubota K, Watanabe H, Ohashi Y . A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012; 96(10):1310-5. PMC: 3463860. DOI: 10.1136/bjophthalmol-2011-301448. View

17.

Inamori Y, Tsujibo H, Ohishi H, Ishii F, Mizugaki M, Aso H . Cytotoxic effect of hinokitiol and tropolone on the growth of mammalian cells and on blastogenesis of mouse splenic T cells. Biol Pharm Bull. 1993; 16(5):521-3. DOI: 10.1248/bpb.16.521. View

18.

Pflugfelder S . Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004; 137(2):337-42. DOI: 10.1016/j.ajo.2003.10.036. View

19.

Amparo F, Dastjerdi M, Okanobo A, Ferrari G, Smaga L, Hamrah P . Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013; 131(6):715-723. PMC: 4167802. DOI: 10.1001/jamaophthalmol.2013.195. View

20.

Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N . A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013; 120(6):1158-65. DOI: 10.1016/j.ophtha.2012.12.022. View